Here is a fact about the human circulatory system that does not get enough attention: veins have valves, and the valves fail. When they fail in your legs, blood that is supposed to head north back toward the heart instead pools where gravity wants it, which is to say downward, in the ankles, producing swelling, aching, skin damage, and, in the ugliest cases, open ulcers that do not heal. Roughly 25 million American adults live with some version of chronic venous insufficiency. It is enormous, common, and - this is the part that made a market - underserved. Nobody had a great, minimally invasive fix.
InterVene, Inc. was founded in 2011 to be that fix. The idea came out of Stanford's Biodesign program, where a fellow named Fletcher Wilson watched surgeons rebuild a broken vein valve by hand in an open operation and had the reasonable thought that a leg should not have to be cut open to repair a valve the width of a coffee stirrer. The technology he built, eventually branded BlueLeaf, did something that sounds faintly like science fiction: it used a catheter and a technique called hydrodissection to peel apart the layers of the vein wall from the inside and coax the patient's own tissue into forming a brand-new, functional valve. No implant. No metal. Just a new flap of the patient's own vein doing the job the old one quit.
Deep valve failure was a huge problem with a very low-tech solution.
It worked, at least early on, and impressively so. In its feasibility data, roughly 93% of patients formed at least one valve, and about 97% of those valves were still open at one year. In December 2021, the FDA granted BlueLeaf a Breakthrough Device Designation, which is the agency's way of saying: this is a serious idea for a serious unmet need, and we will move faster to look at it. For a startup, that is close to a coronation.
The Awkward Part About Breakthroughs
The awkward part about breakthrough designations is that they are not clearances. They are a promise to pay attention, not a permission to sell. And somewhere between the coronation and the checkout counter, InterVene did the thing that separates companies that survive from companies that become cautionary case studies: it looked honestly at what was happening in the operating room and in the market, and it changed its mind about which product should lead. The BlueLeaf outside-U.S. trial was terminated early by the sponsor. The company's public identity quietly, then decisively, shifted to a different device entirely.
That device is Recana, and it solves a problem that BlueLeaf, for all its elegance, did not. When doctors treat blocked deep veins, they often place a stent - a metal scaffold that holds the vessel open. Stents are good until they are not. Blood clots and scar tissue accumulate inside them, and the stent that was supposed to be the solution becomes its own obstruction. This is called venous in-stent restenosis, and it is a genuinely hard problem, because you cannot just stent a stent forever, and the existing tools for cleaning them out were not designed for the job.
Venous ISR and residual native vessel obstructions can lead to long-lasting, debilitating complications for many patients and remain difficult to treat.
Recana is a fully integrated thrombectomy system - the first, InterVene says, designed specifically for venous in-stent restenosis and native-vessel obstructions. Mechanically it is satisfyingly literal: a stainless-steel helical debulking catheter with a sharpened, beveled coring element and a spiral nose cone that lets it cross an occlusion, paired with nitinol collection baskets that capture the material it cores out, plus the introducer and collection sheaths to run the whole thing. It is, in effect, a very precise plumbing snake for a vein that a stent turned into a clogged pipe.
The Detail Investors Notice
The commercially clever detail - the one that makes salespeople and hospital administrators lean forward - is that Recana requires no capital equipment. Hospitals hate capital equipment, because it is expensive, it sits in a room, and it needs a budget cycle and a committee. Recana instead runs on the fluoroscopy and IVUS imaging that vascular specialists already own and already use for deep-venous work. A physician who is already stenting deep veins can adopt Recana without buying a machine or rebuilding a workflow. In medtech, fitting into an existing procedure is often worth more than inventing a better one.
The strategy also has a fingerprint, and it belongs to Jeff Elkins. Elkins joined InterVene as COO in 2018 and became CEO in 2020. Before that he ran Veniti, a venous stent company that Boston Scientific acquired. He has, in other words, personally built the venous stents that fail - which means he knows precisely where and how they fail, and what it would take to fix them. Boston Scientific, notably, is also an InterVene investor. The venous-device world is small, and the people in it tend to keep meeting each other in different chairs.
The funding history reads like a translation of the strategy shift into dollars. An early Series A of about $5.9 million in 2015 got the science going. A $15 million Series B in 2019, led by 3x5 Partners with RiverVest, Boston Scientific, and Correlation Ventures, funded BlueLeaf. Then, in October 2024, a $13 million recapitalized Series A co-led by Treo Ventures and RiverVest funded the final push on Recana - development, clinical cases, the FDA submission, and the start of commercialization. Read in order, the rounds tell you not how much money the company raised but what it kept deciding to become.
The payoff arrived on schedule, in the unglamorous cadence that real medical devices follow. First-in-human in July 2025. FDA 510(k) clearance at the end of October 2025. Thirty cases completed across U.S. and European sites by April 2026, with a broader commercial launch planned for later that year. No shortcuts, no viral moment - just designation, trial, clearance, cases, launch, in that order.
What You Can Actually Do With It
For the people who matter most here - patients with swollen, painful legs and a stent that stopped working - InterVene's answer is now something a specialist can offer without sending them to a distant center or a research protocol. For the vascular surgeons, interventional radiologists, and interventional cardiologists who treat them, Recana is a purpose-built tool for a case they used to improvise around. And for anyone watching how medtech companies actually make it, InterVene is a tidy lesson in the difference between the idea you fall in love with and the product that ships. BlueLeaf earned every accolade. Recana got cleared. Both are wins. Only one, so far, is the business - and the company was clear-eyed enough to know which was which.